about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Aduhelm OK 'bit­ter­sweet' for ALS ad­vo­cates; Con­trast­ing Covid-19 vac­cine read­outs; GSK joins TIG­IT bat­tle; and more

4 years ago
Weekly

Af­ter roller-coast­er week, CRL forces a reck­on­ing on Or­p­hazyme in­vestors — in­flat­ed shares plum­met

4 years ago
FDA+

Rick Klaus­ner's crew of T cell spe­cial­ists wraps $425M IPO, hit­ting Nas­daq along­side Verve, Mol­e­c­u­lar Part­ners

4 years ago
Financing

In a first, Re­gen­eron's an­ti­body cock­tail re­duces deaths for a sub­group of hos­pi­tal­ized Covid-19 pa­tients

4 years ago
R&D
Coronavirus

Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic ...

4 years ago
Financing
Startups

Start­ing fresh in man­u­fac­tur­ing, For­bion start­up re­fu­els to steer next-gen gene ther­a­py ap­proach for ALS, Alzheimer's ...

4 years ago
Financing
Cell/Gene Tx

Soft­Bank, Cor­morant lead hefty $210M in­jec­tion for Umo­ja's three-in-one can­cer im­munother­a­py play

4 years ago
Financing

‘You have to get up on the podi­um’: In­com­ing BIO chair Paul Hast­ings on di­ver­si­ty, drug pric­ing and work­ing with ...

4 years ago
People

Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing ...

4 years ago
Deals

Un­pack­ing the Aduhelm de­ci­sion, Ver­tex's half full glass, a $525M J&J breakup, and more

4 years ago
Weekly

An ex­pen­sive watch, shell com­pa­nies and fake in­voic­es: How two Is­raeli traders tapped in­to a $100M glob­al biotech ...

4 years ago
People
FDA+

Covid-19 roundup: Mod­er­na has filed for vac­cine use in chil­dren; Claim­ing lead­er­ship to com­bat Covid-19, US pledges ...

4 years ago
Coronavirus

Ad­comm mem­ber who warned about risk of ap­prov­ing Bio­gen's ad­u­canum­ab has re­signed fol­low­ing his­toric OK — re­ports

4 years ago
People
FDA+

On a con­tin­ued hunt for Parkin­son's break­throughs, Ab­b­Vie turns to a biotech in its port­fo­lio

4 years ago
Deals

Covid-19 vac­cines for kids: FDA spells out ques­tions on im­muno­bridg­ing, safe­ty fol­lowup ahead of ad­comm

4 years ago
FDA+
Coronavirus

Keen to turn a new page, In­di­v­ior branch­es out, pick­ing up an op­tion for cannabis ad­dic­tion drug

4 years ago
Deals

Der­ma­vant en­gi­neers $160M deal to pay off Glax­o­SmithK­line mile­stones, gear up to launch pso­ri­a­sis cream

4 years ago
Financing

J&J breaks off al­liance with ar­genx, drop­ping CD70 AML drug and ax­ing $1.3B in biobucks

4 years ago
Deals

What ad­u­canum­ab means for Alzheimer's, un­pack­ing a safe­ty bar­ri­er in CAR-T, the push to up­grade a key ALS tri­al tool, ...

4 years ago
Weekly

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is ...

4 years ago
R&D
Cell/Gene Tx

Af­ter ad­mon­ish­ing Ab­b­Vie for Hu­mi­ra patent and pric­ing, Sen Ron Wyden takes Richard Gon­za­lez to task on tax prac­tices

4 years ago
Pharma

Sal­vaging 'ug­ly fruit': Af­ter a se­ries of pro­tein degra­da­tion bets, Ver­sant turns to pro­tein sta­bi­liza­tion plat­form ...

4 years ago
Financing
Startups

No­var­tis stakes an­oth­er PhI­II win for Cosen­tyx, goes deep­er in­to pe­di­atric mar­kets

4 years ago
R&D

Broad In­sti­tute's Er­ic Lan­der con­firmed to Biden cab­i­net; Leg­end re­veals the BC­MA CAR-T da­ta pack­age be­hind pri­or­i­ty ...

4 years ago
News Briefing
First page Previous page 49505152535455 Next page Last page
A service from the Financial Times